Thursday, July 9, 2026

Patent intelligence · US

US 6613792

Treatment of premenstrual syndrome and menopause

expired A61KA61K31/4035A61K31/407A61K31/7056
Status expired
Linked drugs 1
Pipeline programs 6
Years to expiry 0
Applicant portfolio 201
Patent details — US 6613792
Jurisdiction
US
Status
expired
Grant date
Sep 2, 2003
Expiration
Aug 28, 2023
Claims
20
CPC classes
A61K, A61K31/4035, A61K31/407, A61K31/7056
View on Google Patents ↗

Quick answer

US 6613792 (Treatment of premenstrual syndrome and menopause) is held by Designed Nutritional Products, Inc.. Status: expired. Granted Sep 2, 2003. Expires Aug 28, 2023 (0 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
20
CPC classes
A61K, A61K31/4035, A61K31/407, A61K31/7056

More from Designed Nutritional Products, Inc.

Related pharmaceutical patents in our USPTO index.

  1. US 12378245

    Crystalline forms of an RSK inhibitor

    PHOENIX MOLECULAR DESIGNS · Expires Jul 31, 2045

    granted
  2. US 12297243

    Methods and compositions for reducing the immunogenicity of chimeric notch receptors

    Cell Design Labs, Inc. · Expires May 8, 2045

    granted
  3. US 12291058

    Dispersions for additive manufacturing comprising discrete carbon nanotubes

    MOLECULAR REBAR DESIGN, LLC · Expires May 1, 2045

    granted
  4. US 12268695

    Betulin-containing birch bark extracts and their formulation

    Amryt Pharmaceuticals Designated Activity Company · Expires Apr 3, 2045

    granted
  5. US 12247004

    2-amino-N-(amino-oxo-aryl-lambda6-sulfanylidene)acetamide compounds and their therapeutic use

    Oxford Drug Design Limited · Expires Mar 6, 2045

    granted
  6. US 12065498

    Methods of making bispecific anti-CD307E and anti-BCMA chimeric antigen receptors and uses of the same

    Cell Design Labs, Inc. · Expires Aug 15, 2044

    granted
  7. US 12005194

    Configurable oxygen concentrator and related method

    SEPARATION DESIGN GROUP LLC · Expires Jun 6, 2044

    granted
  8. US 11998571

    Pharmaceutical composition comprising stem cell-conditioned medium and exosome isolated therefrom as active ingredient for prevention or treatment of ocular disease

    DESIGNED CELLS CO., LTD. · Expires May 30, 2044

    granted

Frequently asked questions

What is US patent 6613792?

US 6613792 (Treatment of premenstrual syndrome and menopause) is held by Designed Nutritional Products, Inc.. Status: expired. Granted Sep 2, 2003. Expires Aug 28, 2023 (0 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 6613792?

Designed Nutritional Products, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 201 pharmaceutical patents for this assignee.

When does US 6613792 expire?

Our index shows an expiration date of Aug 28, 2023 (0 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.